Keytruda/Inlyta Data Stoke Competition In Kidney Cancer

Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.

Racing
Competition between first-line combinations for advanced RCC is intense • Source: Shutterstock

Competition among drugs vying for a leading position in the future advanced renal cell carcinoma market just got a little tougher, with Merck & Co. Inc. releasing more top-line data from the KEYNOTE-426 study showing a combination of its PD-1 inhibitor, Keytruda (pembrolizumab), with Pfizer Inc.'s tyrosine kinase inhibitor, Inlyta (axitinib), improved overall survival, PFS and ORR in the first-line treatment of condition.

The data were released Feb. 11, 2019, the same day Pfizer and EMD Serono (Merck KGAA) announced that their...

More from Immuno-oncology

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Anticancer

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.